Abstract
Although iron is essential in maintaining the function of the central nervous system, it is a source of reactive oxygen species, which is potentially neurotoxic. Excess iron accumulation has been reported to be associated with many neurodegenerative diseases including Alzheimer disease. Because oxidative damage to neurons is suggested to be an early event of Alzheimer disease, iron deposition in the central nervous system may play a pivotal role in its pathogenesis. In fact, in Alzheimer disease, iron has been demonstrated histochemically to be present in senile plaques and neurofibrillary tangles, the main constituents being amyloid-β and tau, respectively. Since these molecules are key in the pathogenesis of Alzheimer disease, many studies have focused on the relationship of iron with them. However, it has been shown that the oxidative change in neurons is observed before the formation of these pathological hallmarks. This review discusses the suggested role of iron in the progression of Alzheimer disease.
Keywords: alzheimer disease, chelation, neurodegeneration, oxidative stress, redox active iron
Letters in Drug Design & Discovery
Title: Redox Active Iron at the Center of Oxidative Stress in Alzheimer Disease
Volume: 2 Issue: 6
Author(s): Kazuhiro Honda, Paula I. Moreira, Quan Liu, Sandra L. Siedlak, Xiongwei Zhu, Mark A Smith and George Perry
Affiliation:
Keywords: alzheimer disease, chelation, neurodegeneration, oxidative stress, redox active iron
Abstract: Although iron is essential in maintaining the function of the central nervous system, it is a source of reactive oxygen species, which is potentially neurotoxic. Excess iron accumulation has been reported to be associated with many neurodegenerative diseases including Alzheimer disease. Because oxidative damage to neurons is suggested to be an early event of Alzheimer disease, iron deposition in the central nervous system may play a pivotal role in its pathogenesis. In fact, in Alzheimer disease, iron has been demonstrated histochemically to be present in senile plaques and neurofibrillary tangles, the main constituents being amyloid-β and tau, respectively. Since these molecules are key in the pathogenesis of Alzheimer disease, many studies have focused on the relationship of iron with them. However, it has been shown that the oxidative change in neurons is observed before the formation of these pathological hallmarks. This review discusses the suggested role of iron in the progression of Alzheimer disease.
Export Options
About this article
Cite this article as:
Honda Kazuhiro, Moreira I. Paula, Liu Quan, Siedlak L. Sandra, Zhu Xiongwei, Smith A Mark and Perry George, Redox Active Iron at the Center of Oxidative Stress in Alzheimer Disease, Letters in Drug Design & Discovery 2005; 2 (6) . https://dx.doi.org/10.2174/1570180054771545
DOI https://dx.doi.org/10.2174/1570180054771545 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Current Pathogenesis of Alzheimer’s Disease and Plants Derived Neuroprotective Phytoconstituents: A Comprehensive Review
Current Psychopharmacology DL-3-n-Butylphthalide, an Anti-Oxidant Agent, Prevents Neurological Deficits and Cerebral Injury Following Stroke per Functional Analysis, Magnetic Resonance Imaging and Histological Assessment
Current Neurovascular Research Role of Protein Phosphatase 2A in Alzheimers Disease
Current Alzheimer Research Recent Patents on Novel P2X7 Receptor Antagonists and their Potential for Reducing Central Nervous System Inflammation
Recent Patents on CNS Drug Discovery (Discontinued) Pros and Cons of Medical Cannabis use by People with Chronic Brain Disorders
Current Neuropharmacology Frontier View on Nanotechnological Strategies for Neuro-therapy
Current Drug Metabolism The Influence of Vitamin D on Neurodegeneration and Neurological Disorders: A Rationale for its Physio-pathological Actions
Current Pharmaceutical Design Oxidative Stress, Antioxidants and Neurodegenerative Diseases
Current Pharmaceutical Design A New Model for Academics Based Drug Discovery
Current Alzheimer Research The NGF Metabolic Pathway in the CNS and its Dysregulation in Down Syndrome and Alzheimer’s Disease
Current Alzheimer Research Lipoic Acid, a Lead Structure for Multi-Target-Directed Drugs for Neurodegeneration
Mini-Reviews in Medicinal Chemistry Cell and Gene Therapies for Refractory Epilepsy
Current Neuropharmacology The Effect of Lipoic Acid on Macro and Trace Metal Levels in Living Tissues Exposed to Oxidative Stress
Anti-Cancer Agents in Medicinal Chemistry Pharmacogenetics and Pharmacotherapy of Military Personnel Suffering from Post-traumatic Stress Disorder
Current Neuropharmacology Cutting-edge Patents in Alzheimers Disease Drug Discovery: Anticipation of Potential Future Treatments
Recent Patents on CNS Drug Discovery (Discontinued) Inhalational Anesthetic Sevoflurane Rescues Retina Function in Alzheimer’s Disease Transgenic Drosophila
Current Alzheimer Research X-ray Crystallography and Computational Docking for the Detection and Development of Protein–Ligand Interactions
Current Medicinal Chemistry Micro-RNAs, Exercise and Cellular Plasticity in Humans: The Impact of Dietary Factors and Hypoxia
MicroRNA Attenuating Muscle Wasting: Cell and Gene Therapy Approaches
Current Genomics Selegiline (l-Deprenyl) as a Unique Neuroprotective Agent for Chronic Neurodegenerative Disorders- A Lesson from MAO Inhibition
Current Medicinal Chemistry - Central Nervous System Agents